6533b825fe1ef96bd1282011

RESEARCH PRODUCT

Fluorescein- and EGFR-Antibody Conjugated Silica Nanoparticles for Enhancement of Real-time Tumor Border Definition Using Confocal Laser Endomicroscopy in Squamous Cell Carcinoma of the Head and Neck

Jan GosepathRalf KiesslichWolfgang TremelAnna-maria BauerJuergen BriegerRita GieringerAnna WatermannSven Kurch

subject

biologyBiocompatibilityGeneral Chemical EngineeringConfocalEGFRcontrast agentsilica nanoparticlesStainEGFR AntibodyArticlelcsh:Chemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicinechemistrylcsh:QD1-999In vivo030220 oncology & carcinogenesisbiology.proteinGeneral Materials ScienceEpidermal growth factor receptorFluorescein030223 otorhinolaryngologyEx vivoBiomedical engineering

description

Intraoperative definition of tumor free resection margins in head and neck cancer is challenging. In the current proof-of-principle study we evaluated a novel silica nanoparticle-based agent for its potential use as contrast enhancer. We synthesized silica nanoparticles with an average size of 45 nm and modified these particles with the fluorescence stain fluorescein isocyanate (FITC) for particle detection and with epidermal growth factor receptor (EGFR)-targeting antibodies for enhanced tumor specificity. The nanoparticles exhibited good biocompatibility and could be detected in vitro and in vivo by confocal laser scanning microscopy. Additionally, we show in an ex vivo setting that these modified nanoparticles specifically bind to tumor samples and could be detected using a handheld confocal fluorescence endomicroscope. From a clinical point of view, we believe that this method could be used for tumor border contrast enhancement and for better intraoperative definition of R-0 tumor resection.

10.3390/nano9101378http://dx.doi.org/10.3390/nano9101378